DOI QR코드

DOI QR Code

National Strategic Planning For Facilitating the Development of New Drugs in the Korea Food and Drug Administration

국내 신약개발 촉진을 위한 식약청의 국가연구개발 사업 전략수립

  • Published : 2008.12.31

Abstract

It is well understood that developing new drugs is one of the highest value-added businesses in a country; however, the current governments' spending in pharmaceutical research and development(R&D) is minimal in Korea. This paper suggests that different governmental bodies should take in charge of different stages of the R&D process in order to maximize the use of limited government research funding. First, during the initial phase of the drug development, including clinical trials, the Ministry of Education, Science and Technology is the most appropriate governmental organization to support the research. For later procedures such as supporting the industries for exporting developed drugs, legislative approvals, and building infrastructure for future clinical trials should be supported by the Ministry of Knowledge and Economy and the Ministry of Health and Welfare along with the Korea Food and Drug Administration(KFDA). The KFDA, which is the main governmental agency approving newly developed drugs in the market, will need to take a crucial responsibility in the initial phase of the pharmaceutical R&D by guiding the industries with timely and proper information. As a first step, it is recommended to set up and operate a center for supporting new drugs, so that the industries can facilitate the development of marketable drugs which meet customers' needs. Later, in order to expedite the process of exporting and getting approvals of the newly developed drugs from foreign countries, it is necessary to develop new approval system, which includes introduction of the Good Manufacturing Practice (GMP), mandatory validation system, and education program for supporting expertise. Lastly, the KFDA needs to take an active role in developing Korean pharmaceutical industries by communicating with other foreign governments with regards to the globalization of the Korean pharmaceutical industries. For example, as a follow up after the Free Trade Agreement(FTA), active discussion on GLP of Mutual Recognition Agreement(MRA) with the United States of America, should be seriously considered.

Keywords

References

  1. L. R. Burns, 'The business of healthcare innovation' Cambridge University Press (2005)
  2. I. J. Chang, Study on the trends and prospects for clinical trials for domestic medicines, Journal of Health Industry and Technology, Winter (2006)
  3. Datamonitor. Accessed at www.datamonitor.com in Dec. 2008
  4. Korea Food and Drug Administration, The 13th Newly Drug Developed Domestically- Sk 5. Chemical Ltd., Embics, Briefing note for media (2007.07.19)
  5. Korea Food and Drug Administration, 2008 KFDA Research Planning Report (2008)
  6. Korea Food and Drug Administration, Planning To Establish a Center for New DrugsAlong with the development of education programs for drug development without clinical trials, Briefing note for media (2008.09.03)
  7. Korea Food and Drug Administration, Technology Roadmap Planning for KFDA (2008)
  8. Korea Health Industry Development Institute, KHIDI Health Industry Report 1. (2007)
  9. Korea Health Industry Development Institute, A White Paper for Health Industry (2007)
  10. Korea Institute of Science & Technology Evaluation and Planning, Ministry of Science and Technology, Report on the Science and Technology Research (2006)
  11. Korea Institute for Industrial Economics and Trade, The National Statistics on Bio-industries in 2006 (2007)
  12. Y. K. Kwon. Analysis of R&D Trend in Korean Pharmaceutical Industries, Journal of Health Industry and Technology, Winter 57-64 (2006)
  13. C.G. Lee, Organizational Capabilities for Effective Knowledge Creation: An In-depth Case Analysis of Quinolone Antibacterial Drug Discovery Process, Doctoral Degree Thesis, Korea University (2000)
  14. K.M. Lee, G.C. Lee, Analysis on the influence of investment in pharmaceutical R&D on general industries in Korea, Korea Journal of Professional Manager, 10(2) (2007)
  15. K.S. Lee, Analysis on the Trends and Suggestions for Developing Improved Drugs, Korea Pharmaceutical Association (2007)
  16. S.J. Lee, E.H. Lee, Strategic Alliance Model for Korean Pharmaceutical Companies - LGLS Factive Case, Management and Education Research, 10(1), 21 (2006)
  17. S.H. Lim, Studies of Promotion Strategy for New Drug Infrastructure, A Final Report for the Korea Food and Drug Administration (2006)
  18. Ministry of Health and Welfare, The Announcement for Facilitating New Drug Development Using A Natural Substance (2006-2010)- Targeting Development of New Drug for Chronic and Inveterate Diseases, Briefing note for media (2006.04.10)
  19. Ministry of Health and Welfare, The New Research Funding Available for Innovative New Drugs, Improved New Drugs, Bio-Medicines, and Natural Substances Drugs- a total of 51 Billion Won Briefing note for media (2008.02.01)
  20. Ministry of Industry and Resources, Finding Strategies for Development of New Drugs after the Korea-US Free Trade Agreement 2007 Forum for the Globalization of BIO-industries, Briefing note for media (2007.06.28)
  21. Ministry of Knowledge and Economy, Looking for new business partners for Biostar Project- The new R&D project for the world leading Bio-industries, Briefing note for media (2008.05.23)
  22. S. Park, E.J. Kang, E.J. Park, Improvement in Drug Management and Free Trade Agreement between Korea and the United States of America, KoreaInstitute for Health and Social Affairs Research Report (2007)
  23. Rural Development Administration, The Forth Long-Term Research Planning on Agricultural Technology (2006)
  24. J.C. Yoe, Trends and Prospect for Domestic Drug Development, Journal of Health Industry and Technology, Spring-Summer 114 (2007)